From CMS yesterday:
On January 27, 2026, CMS announced the selection of the below list of 15 drugs payable under Medicare Part B and/or covered under Medicare Part D for the third cycle of negotiations (initial price applicability year 2028), based on total expenditures for drugs payable under Part B and/or covered under Part D and other criteria as required by the law.
The drugs selected include:
Trulicity (dulaglutide) – Type 2 diabetes; Type 2 diabetes with cardiovascular disease or multiple cardiovascular risk factorsBiktarvy (bictegravir/emtricitabine/tenofovir alafenamide) – Human immunodeficiency virus type 1 (HIV‑1) infectionOrencia (abatacept) – Rheumatoid arthritis; Psoriatic arthritisCosentyx (secukinumab) – Plaque psoriasis; Psoriatic arthritisErleada (apalutamide) – Prostate cancerKisqali (ribociclib) – Breast cancerEntyvio (vedolizumab) – Crohn’s disease; Ulcerative colitisVerzenio (abemaciclib) – Breast cancerBotox; Botox Cosmetic (onabotulinumtoxinA) – Chronic migraine; Overactive bladder; Spasticity; Other movement disorders (Medicare-covered indications)Lenvima (lenvatinib) – Thyroid cancer; Endometrial cancer; Liver cancer; Kidney cancerXolair (omalizumab) – Asthma; Chronic spontaneous urticariaRexulti (brexpiprazole) – Major depressive disorder; Schizophrenia; Agitation associated with dementia due to Alzheimer’s diseaseXeljanz; Xeljanz XR (tofacitinib) – Rheumatoid arthritis; Psoriatic arthritis; Ulcerative colitisAnoro Ellipta (umeclidinium/vilanterol) – Chronic obstructive pulmonary disease (COPD)Cimzia (certolizumab pegol) – Crohn’s disease; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis
The full CMS Fact Sheet is here.
